Form 4: Neurocrine Biosciences Director Gary Lyons Executes Option and Sells Shares Under 10b5-1 Plan

Director Gary Lyons exercised stock options and sold shares of Neurocrine Biosciences under a pre-arranged 10b5-1 trading plan.

Summary

• On July 16, 2024, Gary A. Lyons, a director of Neurocrine Biosciences Inc., exercised non-qualified stock options to acquire 930 shares of common stock at a price of $42.76 per share.
• Simultaneously, Lyons sold 930 shares of common stock at a weighted average price of $150.0325 per share, with individual sales ranging from $150.00 to $150.18.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on February 13, 2024.
• Following these transactions, Lyons directly owns 119,047 shares of Neurocrine Biosciences, with 113,064 of those shares held in a revocable living trust.
• Lyons also directly owns 11,570 non-qualified stock options.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing detailing stock transactions by a company director. It doesn't inherently convey positive or negative sentiment.

Industry Context

Executive stock transactions are common and closely monitored, especially in the biotech industry. The use of 10b5-1 plans allows insiders to sell shares while avoiding accusations of trading on non-public information.

Comparison to Industry Standards

• Executive compensation and trading activities are typical in publicly traded biotech companies like Neurocrine Biosciences.
• Companies such as Amgen, Biogen, and Gilead Sciences also see regular Form 4 filings related to their executives' stock transactions.
• The use of 10b5-1 trading plans is a standard practice among executives to manage their stock holdings while complying with insider trading regulations.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the small volume of shares involved.
• The transactions do not directly impact employees, customers, suppliers, or creditors.

Key Dates